Registered outcomes15

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 15 of 15

Download this page as JSON

List	Outcome	Time frame
Primary	Maximum Tolerated Dose (MTD) of Mosunetuzumab in Combination with Polatuzumab Vedotin	Cycle 1 to Cycle 2 (cycle length = 21 days)
Primary	Recommended Phase II Dose of Mosunetuzumab in Combination with Polatuzumab Vedotin	Cycle 1 to Cycle 2 (cycle length = 21 days)
Primary	Percentage of Participants with Adverse Events (AE)	Baseline through approximately 90 days after last study treatment
Primary	Best Objective Response Rate (ORR), Defined as CR or Partial Response (PR) at any Time, Based on PET-CT and/or CT Scan, as Determined by the Independent Review Committee (IRC) using Standard Criteria for NHL	Baseline up to approximately 60 months (assessed at screening and then every 3 months for the first year, then every 6 months until disease progression, start of new anti-cancer therapy, or withdrawal)
Secondary	Best ORR (CR or PR at any Time) Based on PET-CT and/or CT Scan, as Determined by the Investigator Using Standard Criteria for NHL	Baseline up to approximately 60 months (assessed at screening and then every 3 months for the first year, then every 6 months until disease progression, start of new anti-cancer therapy, or withdrawal)
Secondary	Best CR Rate on Study Based on PET-CT, and/or CT Scan, as Determined by the Investigator and IRC Using Standard Criteria for NHL	Baseline up to approximately 60 months (assessed at screening and then every 3 months for the first year, then every 6 months until disease progression, start of new anti-cancer therapy, or withdrawal)
Secondary	CR Rate at the Time of Primary Response Assessment (PRA) Based on PET-CT, as Determined by the Investigator and IRC Using Standard Criteria for NHL	Cycle 8 completion (participants receiving mosunetuzumab), or 5-7 weeks after Cycle 6 (polatuzumab+bendamustine+rituximab participants) (Cycle = 21 days)
Secondary	ORR, Defined as CR or PR, at PRA Based on PET-CT as Determined by the Investigator and IRC Using Standard Criteria for NHL	Cycle 8 completion (participants receiving mosunetuzumab), or 5-7 weeks after Cycle 6 (polatuzumab+bendamustine+rituximab participants) (Cycle = 21 days)
Secondary	Duration of Response (DOR) as Determined by the Investigator and IRC Using Standard Criteria for NHL	From the first occurrence of a documented response to disease progression, relapse, or death from any cause, whichever occurs first (up to approximately 60 months)
Secondary	Progression-Free Survival (PFS) as Determined by the Investigator and IRC Using Standard Criteria for NHL	From time of first study treatment to the first occurrence of disease progression, relapse, or death from any cause, whichever occurs first (up to approximately 60 months)
Secondary	Event-Free Survival (EFS) as Determined by the Investigator and IRC Using Standard Criteria for NHL	From time of first study treatment to the first occurrence of disease progression, relapse, initiation of new anti-lymphoma treatment (NALT), or death from any cause, whichever occurs first (up to approximately 60 months)
Secondary	Overall Survival (OS)	From time of first study treatment to death from any cause (up to approximately 60 months)
Secondary	Anti-Drug Antibodies (ADAs) to Mosunetuzumab	At pre-defined intervals from C1D1 through approximately 90 days after the last study treatment
Secondary	ADAs to Polatuzumab Vedotin	At pre-defined intervals from C1D1 through approximately 90 days after the last study treatment
Secondary	Mosunetuzumab Serum Concentration	At pre-defined intervals from C1D1 through approximately 90 days after the last study treatment

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03671018/registered

API reference For AI assistants